Claims
- 1. (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt.
- 2. (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate.
- 3. A pharmaceutical composition comprising(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino) -1-pyridin-3-yl-ethanol), p-toluenesulfonate salt; and. (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 4. A pharmaceutical composition comprising(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino) -1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 5. A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt; or (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino) -1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate.
- 6. A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition comprising(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino) -1-pyridin-3-yl-ethanol), p-toluenesulfonate salt; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 7. A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition comprising(i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino) -1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate; and (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
- 8. The method of claim 5, 6 or 7 wherein said β3-adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, irritable bowel syndrome, inflammatory bowel disease, esophagitis, duodenitis, Crohn's Disease, proctitis, asthma, intestinal motility disorder, ulcer, gastritis, hypercholesterolemia, cardiovascular disease, urinary incontinence, depression, prostate disease, dyslipidemia, and airway inflammatory disorder.
- 9. The method of claim 8 wherein said β3-adrenergic receptor-mediated disease, condition, or disorder is selected from the group consisting of obesity, diabetes, urinary incontinence, and irritable bowel syndrome.
Parent Case Info
This application claims the benefit of U.S. Provisional Application No. 60/360,248 filed Feb. 27, 2002 and incorporated herein by reference in its entirety.
US Referenced Citations (29)
Foreign Referenced Citations (13)
Number |
Date |
Country |
0236624 |
Aug 1993 |
EP |
0543662 |
Sep 1996 |
EP |
0764632 |
Mar 1997 |
EP |
0882707 |
Dec 1998 |
EP |
1236723 |
Sep 2002 |
EP |
WO 9000548 |
Jan 1990 |
WO |
WO 9804526 |
Feb 1998 |
WO |
WO 9821184 |
May 1998 |
WO |
WO 9942455 |
Aug 1999 |
WO |
WO 9945006 |
Sep 1999 |
WO |
WO 0040560 |
Jul 2000 |
WO |
WO 0232897 |
Apr 2002 |
WO |
WO 0248134 |
Jun 2002 |
WO |
Non-Patent Literature Citations (3)
Entry |
U.S. Application No. 10/373119 filed on Feb. 24, 2003 entitled “β3 Adrenergic Receptor Agonists”. |
U.S. Application No. 10/370793 filed on Feb. 20, 2003 entitled “Processes and Intermediates Useful in preparing B3-Adrenergic Receptor Agonists”. |
U.S. Application No. 10/373492 filed on Feb. 25, 2003 entitled “B3-Adrenergic Receptors Agonist Crystal Forms, Processes for the Production Thereof, and Uses Thereof”. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/360248 |
Feb 2002 |
US |